跳至主要内容
临床试验/NL-OMON46123
NL-OMON46123撤回不适用

Circulating tumor DNA exposure in peripheral blood using a novel process: A feasibility study. - Measuring circulating tumor DNA

Quantgene inc.0 个研究点目标入组 500 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Subjects of both cohorts must:
  • - Be of age * 18 years
  • - Provide written consent for study participation;Subjects of cohort 1 must:
  • - Have a diagnosis of one of the following malignancies in clinical stage 0 to IV: non-small lung cancer, gastric cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, colorectal cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, adrenocortical cancer, breast cancer, ovarian cancer, cervical cancer, adrenocortical cancer, melanoma and leukemia.;Subjects of cohort 2 must:
  • - Are planned for surgery in the foreseeable future, to guarantee a blood sample.

排除标准

  • Subjects of cohort 1 must not:
  • - Have been treated for above diagnosed malignancy ;Subjects of cohort 2 must not
  • - Have been diagnosed or treated for a malignancy previously

研究者

相似试验